Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Radiation-Induced Solid Tumors
NCT02864316Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2016
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in radiation-induced solid tumor, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Dec 2016; status: terminated.
02
Drugs
03
Conditions
radiation-induced solid tumor
Beyond the preview
Go deeper on NCT02864316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02864316.